IP Library › Granted Patent US 10,428,381
Granted Patent B2
US 10,428,381 · App. 15/075,370 · Granted Oct 1, 2019

Methods for detection of nucleotide modification

Inventors: Michael John Booth (Cambridge, GB); Shankar Balasubramanian (Cambridge, GB)
Assignee: Cambridge Epigenetix Limited
C12Q1/6876C01G55/002C07H1/00C07H21/02C07H21/04C12Q1/6806C12Q1/6827C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,428,381
App. No.
15/075,370
Granted
Oct 1, 2019
Kind
B2
Abstract

This invention relates to the identification of modified cytosine residues, such as 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC) and 5-formylcytosine (5fC) to be distinguished from cytosine (C) in a sample nucleotide sequence. Methods may comprise oxidizing or reducing a first portion of polynucleotides which comprise the sample nucleotide sequence; treating the oxidized or reduced first portion and a second portion of polynucleotides with bisulfite; sequencing the polynucleotides in the first and second portions of the population following steps ii) and iii) to produce first and second nucleotide sequences, respectively and; identifying the residue in the first and second nucleotide sequences which corresponds to a cytosine residue in the sample nucleotide sequence. These methods may be useful, for example in the analysis of genomic DNA and/or of RNA.

Claims (12)

1. A method comprising:

contacting a sample comprising a 5-hydroxymethylcytosine with a perruthenate oxidizing agent, wherein said perruthenate oxidizing agent selectively converts said 5-hydroxymethylcytosine to 5-formylcytosine.

2. The method of claim 1 , wherein said sample comprises a nucleotide sequence.

3. The method of claim 1 , wherein said perruthenate oxidizing agent is KRuO 4 .

4. The method of claim 2 , wherein said nucleotide sequence comprises genomic DNA.

5. The method of claim 2 , wherein said nucleotide sequence comprises RNA.

6. The method of claim 2 , wherein said nucleotide sequence is immobilized.

7. The method of claim 2 , further comprising confirming a presence of said 5-hydroxymethylcyto sine.

8. The method of claim 7 , wherein said confirming comprises amplifying said nucleotide sequence.

9. The method of claim 7 or 8 , wherein said confirming comprises sequencing said nucleotide sequence.

10. The method of claim 2 , further comprising reducing said nucleotide sequence.

11. The method of claim 1 , wherein said contacting occurs under aqueous conditions.

Assignments (3)
CHANGE OF NAME Recorded Feb 13, 2024
From: CAMBRIDGE EPIGENETIX LIMITED
To: BIOMODAL LIMITED
Reel/Frame 066450/0026 →
CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST INVENTORS NAME PREVIOUSLY RECORDED ON REEL 041606 FRAME 0494. ASSIGNOR(S) HEREBY CONFIRMS THE FIRST ASSIGNORS NAME SHOULD BE --MICHAEL JOHN BOOTH--. Recorded May 15, 2019
From: BOOTH, MICHAEL JOHN; BALASUBRAMANIAN, SHANKAR
To: CAMBRIDGE EPIGENETIX LIMITED
Reel/Frame 051005/0698 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2017
From: BROWN, MICHAEL JOHN; BALASUBRAMANIAN, SHANKAR
To: CAMBRIDGE EPIGENETIX LIMITED
Reel/Frame 041606/0494 →
Continuity (6)
Continuation 14235707
Provisional Application 61513356 · Jul 29, 2011
Provisional Application 61605702 · Mar 1, 2012
Provisional Application 61623461 · Apr 12, 2012
Provisional Application 61641134 · May 1, 2012
Related Publication 20160258014A1 · Sep 8, 2016
Cited By (2)
US 12,540,319 US 12,630,866